NeuroXess 表示，一名瘫痪患者在植入后 5 天内即可控制电脑游标，目前锁定瘫痪与肌萎缩侧索硬化症（ALS）等重度失能。自 2025 年 2 月以来，中国已启动 10 项侵入式脑晶片临床试验，融资活动也加速：2025 年前 11 个月，BCI 新创至少完成 24 轮融资，年增 30%。NeuroXess 的方案是在脑表面放置聚醯亚胺与金属网格，并以穿出颅外的导线连接胸腔内的电池组，旨在避免其称早期动物实验中、将电极插入脑组织所见的疤痕形成与讯号衰减。
竞争比较主要取决于效能与侵入程度。Neuralink 正在进行一项涵盖全球 21 人的临床试验，并称受试者已达到并超过 10 bits per second；相较之下，NeuroXess 公布最高可达 5.2 bits per second，差距在把想法转成语音等复杂任务上尤其关键。NeuroXess 主张其表面网格可在不穿透组织的情况下、于更大范围撷取讯号；Neuralink 则表示其显微线程约为人类头发厚度的 0.1，放置方式可避开敏感组织并减轻结疤。中国的规模或可进一步加快迭代：NeuroXess 创办人称可招募族群「非常庞大」，且中国有「数百万」人完全丧失运动与语言能力；但专家提醒，除非明确必要，脑部手术的采用仍将受限，而非侵入式系统也仍受物理限制，因讯号穿过骨骼会衰减，即便将超音波或磁成像与更好的 AI 结合，准确度也可能仅能随时间逐步提升。
China is backing brain-computer interface (BCI) “champions” to compete with US players such as Elon Musk’s Neuralink, and the policy push is translating into faster moves from lab work into human testing. Shanghai start-up NeuroXess, founded in 2021, says official support and investor enthusiasm helped it shorten the time to commercialization, framing the advantage as speed: “time is equal to money.” Beijing designated BCI as a nationally strategic sector in 2024 and issued a roadmap targeting the creation of 2 to 3 “world-class” companies by 2030, alongside looser regulation, more clinical experimentation, and mobilized capital.
NeuroXess reported that a paralysed patient could control a computer cursor within 5 days of implantation, and it is currently targeting severe disabilities such as paralysis and amyotrophic lateral sclerosis (ALS). Since February 2025, 10 clinical trials for invasive brain chips have been launched in China, and financing activity accelerated: at least 24 funding rounds for BCI start-ups closed in the first 11 months of 2025, up 30% year on year. NeuroXess’s approach places a polyimide-and-metal mesh on the brain surface, connected by wiring outside the skull to a battery pack in the chest, aiming to avoid the scarring and signal degradation it says it saw in early animal tests with electrodes inserted into brain tissue.
Competitive comparisons hinge on performance and invasiveness. Neuralink is running a 21-person worldwide clinical trial and says participants have reached and exceeded 10 bits per second, versus up to 5.2 bits per second announced by NeuroXess, a gap that matters for complex tasks like turning thoughts into speech. NeuroXess argues its surface mesh captures signals over a wider area without penetrating tissue, while Neuralink says its microscopic threads, about 0.1 the thickness of a human hair, are placed to avoid sensitive tissue and mitigate scarring. China’s scale may further speed iteration: NeuroXess’s founder cites a “very large” recruitable pool and “several million” people in China with total motor and language loss, while experts caution that brain surgery adoption will stay limited unless clearly necessary and that non-invasive systems still face physics constraints as signals weaken through bone, even if combining ultrasound or magnetic imaging with better AI could improve accuracy over time.